Allogene Therapeutics
Matt Muldoon has a diverse work experience in various roles and companies. Matt is currently working at Allogene Therapeutics as the Sr. Director, Business Development since June 2022. Matt also held the position of Sr. Director Supplier Management at Allogene Therapeutics from August 2020 to June 2022. Prior to that, they worked at Bayer Pharmaceuticals from 2012 to 2020, where they held several roles including Head of PS Biotech Procurement, Director US Direct Material Sourcing, Associate Director Medical Device Lifecycle Sourcing, Strategic Sourcing Manager - Biotech Raw Materials, and Strategic Sourcing Manager - Biotech Raw Materials, APIs. Before joining Bayer Pharmaceuticals, they worked at Merck Sharp & Dohme from 2002 to 2012, where they held positions such as Sourcing Manager / Category Lead - Clinical Trial Supply Chain, Clinical Research Sourcing Analyst, Sr. Vaccine Manufacturing Supervisor / Technical Advisor, and Vaccine Manufacturing Supervisor.
Matt Muldoon obtained their Bachelor of Arts degree in Biology and Chemistry from the University of Richmond in 2002. Following this, they pursued their Master's in Business Administration (MBA) from Drexel University - Lebow College of Business Administration, completing it in 2011.
This person is not in the org chart
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.